Short answer
Exelixis Inc (EXEL) filed its Q1 2019 10-Q quarterly report on May 1, 2019 for the quarter ended Mar 29, 2019.
Exelixis Inc Q1 2019 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Total revenue $215.5M, up from $213.7M YoY, with net product revenue $179.6M vs $134.3M
- CABOMETYX strongest product, $175.9M vs $128.9M, while COMETRIQ declined to $3.7M from $5.3M
- Net income $75.8M vs $115.9M; effective tax rate 16.4% vs 2.1%
- Cash and investments $1.0B vs $851.6M; operating cash flow $161.6M vs $71.8M
- 2019 R&D expected to increase; competition, reimbursement pressure and healthcare cost containment remain headwinds
Risk Factors
- Newly emphasized compliance risk: Senate Finance Committee inquiry into pharmaceutical patient-assistance charitable foundations launched March 2019
- Regulatory risk: CCPA takes effect January 1, 2020, adding civil penalties and private data-breach actions
- Near-term market risk: ICI-based oncology combinations intensify competition in CABOMETYX indications
- Financial risk: LIBOR phaseout by end-2021 could increase borrowing costs or reduce investment values
- Liquidity risk: $1.0 billion cash and investments as of March 31, 2019, funding continued pipeline investment and commercialization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Exelixis Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.